3E Bioventures Capital
QuietFiled to raiseGrand Cayman, Cayman IslandsHealthcare, BiotechnologyLast fund filed 2019
1 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| 3E Bioventures Capital IIFiled to raise in 2019, with no closing reported yet. | 2019 | $200M | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
1 partner is named across this firm’s filings, 1 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Qianye Liu | Quiet | Digital health | 2 | 0 |
Too few companies classified yet to infer a focus. 1 of 2 portfolio companies are classified.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of 3E Bioventures Capital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Frist Cressey Ventures | 1 | PROFUSA |
A shared board seat: a company where filings name a 3E Bioventures Capital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.